PLSEPulse Biosciences Inc
$25.77
$0.93
(3.74%)
Closed $25.77
$0.00
(0.00%)
After Hours
EarningsAug 14
Mkt Cap$1.72B
Vol218,634.00
Fundamentals
Mkt Cap
$1.72B
Volume
-
52W High
$28.53
52W Low
$12.56
PE Ratio
-23.36
Avg. Volume
391,226.34
EPS (Annual)
-$1.08
Rev/Employee
$3,017.24
Earnings
Aug 14
44
Bearish Sentiment
How do you feel about PLSE?
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences Management is...
Business Wire
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors...
Yahoo! Finance: News
ATM Equity Purchases by Pulse Biosciences Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced its Co-Chairmen of the Board, Robert Duggan...
Business Wire
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming BofA...
Business Wire
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Pulse Biosciences (NASDAQ:PLSE) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05...
MarketBeat
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +15.63% and -19.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced business updates and...
Business Wire
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday
Pulse Biosciences (NASDAQ:PLSE) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-pulse-biosciences-inc-stock...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest PLSE News
ViewPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Business Wire
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Zacks
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Yahoo! Finance: News
Advertisement|Remove ads.